Can Western Pharma bring biologics to China? Yes, if the price is right, say CEOs

Biologics are the next challenge for multinationals looking to enter the lucrative Chinese market, but such drugs must offer value and genuine innovation, say the CEOs of Merck KGaA and Chi-Med.

“Referring to China as an emerging market is a bit like referring to Google as a new economy,” said Stefan Oschmann, CEO Pharma at Merck KGaA, during a panel discussion discussing new market opportunities at last month’s FT Global Healthcare and Biotech Conference in London, UK.

Approximately 40% of the Germany-headquartered firm’s revenues come from markets which are generally described as ‘emerging,’ with China being a major focus of investment for the Merck Serono division.

Last year China's healthcare spend was around $132bn, up from $5bn in 2000, the panel said but for multinationals looking at entering this lucrative market the challenge is to offer high quality branded products at affordable prices, according to Oschmann.

“Traditionally business [in China] has relied on classical medications which are off-patent medicines,” he told delegates. “That has worked for a number of companies pretty well, but going forward the challenge is to introduce successfully biologics. This is where we are seeing a mixed result across the industry.”

So far Merck has expanded into the region with a €150m ($188m) R&D centre and is building an €80m small molecule drug plant in Nantong , but is yet to have invested in biologics capacity. However, the firm is expected to capitalise on the demand for life science tools and supplies in China through the planned $17bn acquisition of Sigma-Aldrich .

Also on the panel was Christian Hogg, CEO of Hutchinson China MediTech (Chi-Med) – a firm which signed a co-promotion agreement with Merck Serono to market cardiovascular prescription drug products in China in October – who was unconvinced Western companies will find a market for their biologic drugs in China.

“So many targeted therapies monoclonal antibodies are not appropriate for China,” he said. “There’s no point in coming to China with a $10,000 per cycle targeted therapy as 1.4 billion people won’t be able to afford it.”

Branded Generics – A Waste of Time

Hogg was also scathing of multinationals pushing branded generics in the country. “You are wasting your time with branded generics as there are high numbers of Chinese pharma companies whose manufacturing qualities in generics are improving daily.

“You can’t charge 30-50% more for a multinational brand name on the same product that’s being manufactured by a local Chinese company,” he continued, adding this has led to much of the corruption among Big Pharma firms in China in the past few years, as they try to push physicians to prescribe their more expensive local drugs.

Instead, Western pharma should bring “genuine innovations that are accessible to the people of China” in order to compete, and overcome hurdles such as support from the Government.

“It’s about value. Give them products which are relevant, affordable and sensible and you will get all the support you need.”

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客